Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more
Merus BV (MRUS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.128x
Based on the latest financial reports, Merus BV (MRUS) has a cash flow conversion efficiency ratio of -0.128x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-84.92 Million) by net assets ($661.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Merus BV - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Merus BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Merus BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merus BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Argan Inc
NYSE:AGX
|
0.411x |
|
Compeq Manufacturing Co Ltd
TW:2313
|
0.043x |
|
Viavi Solutions Inc
NASDAQ:VIAV
|
0.051x |
|
Phoenix Group Holdings PLC
PINK:PNXGF
|
0.591x |
|
BYD CO.LTD SDR/0,10 O.N.
F:4BY1
|
N/A |
|
Aker BP ASA
PINK:AKRBF
|
0.105x |
|
ViaSat Inc
NASDAQ:VSAT
|
0.157x |
|
Summit Materials Inc
NYSE:SUM
|
0.052x |
Annual Cash Flow Conversion Efficiency for Merus BV (2013–2024)
The table below shows the annual cash flow conversion efficiency of Merus BV from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $650.36 Million | $-185.84 Million | -0.286x | +28.40% |
| 2023-12-31 | $356.34 Million | $-142.21 Million | -0.399x | +34.23% |
| 2022-12-31 | $247.06 Million | $-149.90 Million | -0.607x | -221.76% |
| 2021-12-31 | $316.20 Million | $-59.63 Million | -0.189x | +75.87% |
| 2020-12-31 | $102.26 Million | $-79.90 Million | -0.781x | -62.71% |
| 2019-12-31 | $131.30 Million | $-63.05 Million | -0.480x | -8.93% |
| 2018-12-31 | $105.09 Million | $-46.33 Million | -0.441x | +43.58% |
| 2017-12-31 | $57.45 Million | $-44.88 Million | -0.781x | -3.32% |
| 2016-12-31 | $35.79 Million | $-27.06 Million | -0.756x | +7.08% |
| 2015-12-31 | $30.94 Million | $-25.18 Million | -0.814x | -119.85% |
| 2014-12-31 | $-4.33 Million | $-17.74 Million | 4.099x | +551.01% |
| 2013-12-31 | $10.58 Million | $-9.62 Million | -0.909x | -- |